Source published October 15, 2026: Universal Brain vendor announcement distributed through Business Wire. FDA clearance was independently checked in the agency's K253767 database record and 510(k) summary.
From clearance to clinical workflow Universal Brain says its UB ERP System was installed at Acacia Clinics' Sunnyvale campus on October 8, with staff training completed alongside the installation. The companies describe this as the system's first clinical deployment following FDA clearance.
The initial three-month pilot is designed to learn how rapid EEG and event-related-potential assessment can fit into a psychiatry clinic's existing workflow and add objective information alongside established evaluations. That practical implementation question is the news here. No patient outcome results have been reported.
What FDA cleared FDA's public record shows a June 30, 2026 substantially-equivalent decision for K253767, a Class II electroencephalograph system. The cleared use covers acquiring, displaying, analyzing, storing and reporting EEG signals and ERPs from adults and adolescents in a healthcare facility or clinic under a healthcare professional's direction.
The FDA summary is also explicit about the boundary: the system does not draw a diagnostic conclusion. A clinical expert must interpret its EEG and ERP recordings together with other clinical findings. Clearance therefore supports lawful marketing for the stated use, not proof that the deployment improves diagnosis, treatment selection or patient outcomes.
What the platform includes The regulatory summary describes a cap-based EEG device with dry and disposable electrode components and a Windows application that presents tasks, collects signals and produces an ERP report. The vendor emphasizes reduced setup burden compared with gel-based acquisition. The deployment announcement does not yet provide peer-reviewed workflow, reliability or outcome data from Acacia.
Why it matters Moving a cleared EEG and ERP platform from development into routine clinical operations creates a useful opportunity to study setup time, data quality, staff training, interpretation and fit with existing care. Results from the pilot will be needed before broader claims about clinical value can be made.
Disclosure This is coverage of a vendor announcement, independently cross-checked against FDA records. It is not a clinical endorsement. Prepared with AI assistance; source release, FDA database record and 510(k) summary checked October 18, 2026.